Latest News

Oryzon completes funding

Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.
Dies ist eine Bildunterschrift.
Dies ist eine Bildunterschrift. Bildunterschriften sind immer eine, maximal zwei, Zeilen lang. Dies ist die zweite Zeile einer Bildunterschrift.


by Uta Mommert

Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.

The financing round has been subscribed by several Spanish commercial banks in the form of long term loans at the current interest rates in the Spanish bank market. “These funds complement the capital increase that the company made upon its listing on the Spanish Market, and are a key component to our strategic Financial Plan,” said Enric Rello, CFO of Oryzon. “These funds will be important to further advance our clinical programmes in Alzheimer’s disease and in other devastating diseases.”

Oryzon Genomics has currently two programmes in clinical stage with different LSD1 inhibitors in cancer and neurodegeneration. Recently, the biopharmaceutical company started a Phase I trial of its oral LSD1-MAOB dual inhibitor ORY-2001. With a successful study outcome, ORY-2001 is expected to proceed to a Phase II study in Alzheimer’s disease patients in early 2017.

© european-biotechnology-news.com/um

Priothera closes €30m Series A financing

The Irish cancer specialist Priothera Limited said it will use the the proceed sto advance its S1P receptor modulator mocravimod to Ohase...

Swiss Noema Pharma raises CHF54m in Series A financing

It is one of the largest Series A rounds in Europe: Led by Sofinnova Partners and Polaris Partners, rare neurological diseases start-up Noema Pharma...

LSP reports first closing of dementia fund

The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

Centogene and Anylam launch clinical programme

ATTRv is an autosomal dominant condition caused by a pathogenic variant in the TTR gene coding for transthyretin (prealbumin)....

3P Bio to manufacture SpyBiotech vaccine

Under the agreement, Navarra-based CDMO 3P Biopharmaceuticals will produce cGMP lots for Phase I testing of SpyBiotech’s (Oxford) vaccine candidate...

Moderna to file for EU approval of mRNA-1273 vaccine

Modernas primary analysis of the COVE Phase III data was based on 196 cases, of which 185 cases of COVID-19 were observed in the placebo group versus...

Novo Holdings creates Hemab

Hemab ApS will combine antibody know-how from Genmab A/S and Novo Nordisk to fight medically underserved orphan bleeding disorders.  The company...